FDA approves Erbitux to treat late-stage head and neck cancer

The U.S. Food and Drug Administration today approved Erbitux (cetuximab) for use with chemotherapy to treat patients with late-stage (metastatic) head and neck cancer.

Home | Copyright 2008-2024 FoodandDrugRecall.org